Skip to content
Medical Health Aged Care, Science

ARC grant to fuel research into cellular ageing

Centenary Institute 2 mins read
Professor Jennifer Gamble

Centenary Institute researchers have been awarded an Australian Research Council (ARC) Discovery Project grant worth $709,714 to advance understanding of the intricate mechanisms underlying cellular ageing.


Professor Jennifer Gamble and Dr Yanfei (Jacob) Qi will lead the study, investigating the ageing processes of blood vessel cells. They will focus on the lipid (fat) composition of the cell membrane as a potential crucial determinant in how and when cells begin to show the adverse effects of age.


Outcomes from the study say the researchers, could include the identification of new indicators for unhealthy or premature cell ageing which contribute to age-related disease such as heart disease and dementia.


Lead Chief Investigator on the project Professor Gamble, from the Centenary Institute’s Centre for Healthy Ageing said that ageing at the cellular level determines the health span of individuals.


“Our project seeks to fill a gap in our understanding of what happens as our cells age, with a particular focus on one of the key cell types found in blood vessels, endothelial cells," said Professor Gamble.


“Endothelial cells are important because they line our blood vessels. When they age they can stop working properly, leading to heart problems, high blood pressure, blood clot formation and other issues. So, keeping these cells healthy is vital for our overall well-being,” she said.


Dr Qi from the Centenary Institute’s Centre for Cardiovascular Research and an expert on the study of lipids said that changes in the lipid composition of a cell’s membrane could affect its properties and functions, as well as its response to stress.


"Our study seeks to see how these lipid membrane changes might contribute to the overall ageing of endothelial cells and their capacity to function optimally over time. This study may also indicate why some people age healthily,” said Dr Qi.


“This knowledge will provide us with a foundation to explore strategies aimed at decelerating the ageing process of these cells, ultimately with a view to fighting disease and enhancing health outcomes.”


The ARC Discovery Projects scheme supports excellent basic and applied research to expand Australia’s knowledge base and research capability.





About us:

About the Centenary Institute

The Centenary Institute is a world-leading independent medical research institute, closely affiliated to the University of Sydney and the Royal Prince Alfred Hospital. Our research spans the critical areas of cancer, cardiovascular disease, rare diseases, inflammation, infectious diseases, healthy ageing and biomedical AI. Our strength lies in uncovering disease mechanisms and applying this knowledge to improve diagnostics and treatments for patients.


For more information about the Centenary Institute, visit


Contact details:

For all media and interview enquiries, please contact

Tony Crawshaw, Media and Communications Manager, Centenary Institute on 0402 770 403 or email:


More from this category

  • Medical Health Aged Care
  • 18/07/2024
  • 00:00
Dementia Australia

100,000 people worldwide have downloaded BrainTrack – have you?

More than 100,000 people worldwide have downloaded BrainTrack, the multi-award-winning free app supporting people to take a positive step forward in their brain health. Since its release in October 2022 BrainTrack has been downloaded across 202 countries including Australia, India and the United States. BrainTrack, a Dementia Australia initiative, helps people privately monitor and better understand potential changes in their cognition over time through fun, travel-themed games that have been adapted from validated cognitive testing. Users can share their results with their doctor to support the early identification of cognitive changes that may warrant further testing. Dementia Australia ExecutiveDirectorServices,AdvocacyandResearch Dr…

  • Medical Health Aged Care, Science
  • 17/07/2024
  • 14:00
De Motu Cordis

De Motu Cordis (DMC) announces plans for the next stage of development for DMC-IH1, an inhaled epinephrine drug device combination product

Brisbane, QLD – 17 July 2024 – De Motu Cordis (DMC) today announced plans for the next stage of development with its Contract Development and Manufacturing Organization (CDMO) partner, Catalent, at Catalent’s Boston, Morrisville and San Diego sites. These expansion plans encompass services from drug product manufacturing and device assembly through to commercial launch of DMC’s product, DMC-IH1. DMC-IH1 is an inhaled epinephrine drug-device combination product being developed for the treatment of anaphylaxis using a dry powder inhaler (DPI). Catalent DPI drug delivery services offer end-to-end solutions to bring customers through the entire clinical pharma journey by leveraging the commercial…

  • Medical Health Aged Care, Women
  • 17/07/2024
  • 07:00
Monash University

Study underlines the importance of supporting primary care clinicians to deliver early medical abortion and long acting reversible contraception

The impetus for additional support and training for clinicians wanting to deliver important sexual and reproductive services has received a boost with the release of Monash University-led research. Published in BMJ – Sexual and Reproductive Health, the AusCAPPS study found that GPs, nurses and pharmacists seek peer support and online resources to deliver long-acting reversible contraception (LARC) and early medical abortion (EMA) in Australian primary care.Experienced and emerging providers of LARC and EMA sought support regarding clinical issues online from AusCAPPS, which is the Australian Contraception and Abortion Primary Care Practitioner Support Network, an evidence-based virtual community of practice launched…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.